Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q8IYM9
UPID:
TRI22_HUMAN
Alternative names:
50 kDa-stimulated trans-acting factor; RING finger protein 94; RING-type E3 ubiquitin transferase TRIM22; Staf-50; Tripartite motif-containing protein 22
Alternative UPACC:
Q8IYM9; Q05CQ0; Q15521
Background:
E3 ubiquitin-protein ligase TRIM22, also known as RING finger protein 94 and Tripartite motif-containing protein 22, plays a pivotal role in innate and adaptive immunity. It restricts the replication of various viruses, including HIV-1, hepatitis B and C, and Zika virus, by promoting ubiquitination and degradation of viral proteins. Additionally, TRIM22 regulates antiviral immunity by co-regulating the RIGI/NF-kappa-B pathway.
Therapeutic significance:
Understanding the role of E3 ubiquitin-protein ligase TRIM22 could open doors to potential therapeutic strategies.